Revenue has plummeted to a negligible $3.6K in 2025Q3, driving the company into a structural deficit with an unsustainable operating margin of -906.5%.
| Metric | TTM | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 |
|---|
| Sales/Revenue | 728.2K | 1.62M | 1.63M | 1.51M | 1.42M | 1.25M | 1.41M | 1.41M | 654.84K | 456.5K | 654.35K | 951.56K | 468.13K | 188.77K | 96.64K | 288 | 15.74K | 0 |
| Revenue Growth % | -47.2% | -0.24% | 8.12% | 5.97% | 13.45% | -11.28% | -0.01% | 115.57% | 43.45% | -30.24% | -31.23% | 103.27% | 147.98% | 95.34% | 33454.51% | -98.17% | - | - |
| Cost of Goods Sold | 362.32K | 826.14K | 609.21K | 505.11K | 487.02K | 447.19K | 531.81K | 415.76K | 148.04K | 181.62K | 303.98K | 385.32K | 189.71K | 128.54K | 56.08K | 140 | 7K | 0 |
| COGS % of Revenue | - | 50.88% | 37.43% | 33.55% | 34.28% | 35.71% | 37.68% | 29.45% | 22.61% | 39.79% | 46.46% | 40.49% | 40.52% | 68.09% | 58.03% | 48.61% | 44.48% | - |
| Gross Profit | 365.87K | 797.68K | 1.02M | 1M | 933.66K | 805.08K | 879.75K | 995.89K | 506.79K | 274.88K | 350.37K | 566.24K | 278.42K | 60.23K | 40.56K | 148 | 8.74K | 0 |
| Gross Margin % | 50.24% | 49.12% | 62.57% | 66.45% | 65.72% | 64.29% | 62.32% | 70.55% | 77.39% | 60.21% | 53.54% | 59.51% | 59.48% | 31.91% | 41.97% | 51.39% | 55.52% | - |
| Gross Profit Growth % | - | -21.68% | 1.81% | 7.14% | 15.97% | -8.49% | -11.66% | 96.51% | 84.37% | -21.55% | -38.12% | 103.38% | 362.24% | 48.51% | 27303.38% | -98.31% | - | - |
| Operating Expenses | 10.72M | 11.74M | 13.14M | 27.03M | 21.36M | 26.17M | 23.52M | 8.86M | 8.25M | 6.8M | 4.75M | 7.03M | 9.21M | 7.22M | 4.15M | 1.21M | 2.45M | 1.67M |
| OpEx % of Revenue | - | 722.81% | 807.04% | 1795.73% | 1503.67% | 2089.41% | 1666.55% | 627.44% | 1260.37% | 1489.81% | 725.91% | 739.17% | 1966.53% | 3824.68% | 4290.22% | 418668.06% | 15583.57% | - |
| Selling, General & Admin | 8.51M | 8.89M | 9.06M | 12.47M | 11.71M | 10.94M | 11.69M | 7M | 8.25M | 5.64M | 4.75M | 7.03M | 9.21M | 7.22M | 4.15M | 2.07M | 2.01M | 1.35M |
| SG&A % of Revenue | - | 547.24% | 556.43% | 828.29% | 824.02% | 873.37% | 828.45% | 495.6% | 1260.37% | 1236.11% | 725.91% | 739.17% | 1966.53% | 3824.68% | 4290.22% | 720159.03% | 12743.13% | - |
| Research & Development | 1.05M | 25.99K | 122.31K | 320.32K | 315.85K | 372.71K | 2.96M | 1.86M | 289K | 406K | 261K | 394K | 235.05K | 15K | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | 1.6% | 7.51% | 21.28% | 22.23% | 29.76% | 209.71% | 131.84% | 44.13% | 88.94% | 39.89% | 41.41% | 50.21% | 7.95% | - | - | - | - |
| Other Operating Expenses | 1.16M | 2.83M | 3.96M | 14.24M | 9.34M | 14.86M | 8.87M | 68.48K | 0 | 1.16M | 0 | 0 | 0 | 0 | 0 | -868.29K | 447K | 0 |
| Operating Income | -10.35M | -10.94M | -12.12M | -26.03M | -20.43M | -25.36M | -22.64M | -7.86M | -7.75M | -6.53M | -4.4M | -6.47M | -8.93M | -7.16M | -4.11M | -1.21M | -2.44M | -1.67M |
| Operating Margin % | -1421.38% | -673.69% | -744.47% | -1729.28% | -1437.95% | -2025.12% | -1604.23% | -556.89% | -1182.98% | -1429.59% | -672.36% | -679.67% | -1907.05% | -3792.77% | -4248.26% | -418616.67% | -15528.05% | - |
| Operating Income Growth % | - | 9.72% | 53.45% | -27.44% | 19.45% | -11.99% | -188.05% | -1.48% | -18.7% | -48.33% | 31.97% | 27.55% | -24.69% | -74.4% | -240.52% | 50.66% | -46.04% | - |
| EBITDA | -9.41M | -10.24M | -11.87M | -24.72M | -19.09M | -24.34M | -21.94M | -7.71M | -7.68M | -6.44M | -4.32M | -6.4M | -8.78M | -7.16M | -4.1M | -1.2M | -2.44M | -1.67M |
| EBITDA Margin % | -1291.94% | -630.85% | -729.43% | -1642.06% | -1343.61% | -1943.28% | -1554.29% | -546.43% | -1172.05% | -1411.55% | -660.36% | -673.04% | -1875.27% | -3792.2% | -4244.97% | -417773.26% | -15508.72% | - |
| EBITDA Growth % | 26.04% | 13.72% | 51.97% | -29.51% | 21.56% | -10.92% | -184.43% | -0.5% | -19.11% | -49.12% | 32.53% | 27.05% | -22.63% | -74.51% | -240.95% | 50.7% | -45.91% | - |
| D&A (Non-Cash Add-back) | 942.58K | 695.66K | 244.79K | 1.31M | 1.34M | 1.02M | 704.88K | 147.63K | 71.56K | 82.36K | 78.57K | 63.04K | 148.76K | 1.08K | 3.17K | 2.43K | 3.04K | 569 |
| EBIT | -84.04M | -10.94M | -12.12M | -15.27M | -13.47M | -12.48M | -13.77M | -7.86M | -6.05M | -6.53M | -4.4M | -6.46M | -8.77M | -7.16M | -4.26M | -1.21M | -2.81M | -1.67M |
| Net Interest Income | 0 | 0 | 0 | -10.65M | 0 | 0 | 0 | 0 | 0 | -3 | -390.89K | -377.72K | -636.5K | -259.35K | -230.37K | -147.09K | -78.94K | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 10.65M | 0 | 0 | 0 | 0 | 0 | 3 | 390.89K | 377.72K | 636.5K | 259.35K | 230.37K | 147.09K | 78.94K | 89.34K |
| Other Income/Expense | -73.66M | 79.27K | 100.17K | 296.02K | 109.8K | -524.36K | 3.25M | -2.23M | 50.51K | -3 | -390.89K | -366.12K | -619.51K | -262.46K | -381.49K | -147.09K | -448.58K | -89.34K |
| Pretax Income | -84.01M | -10.86M | -12.02M | -25.74M | -20.32M | -25.88M | -19.39M | -10.09M | -7.75M | -6.53M | -4.79M | -6.83M | -9.41M | -7.42M | -4.49M | -1.35M | -1.76M | 0 |
| Pretax Margin % | -11537.01% | -668.81% | -738.32% | -1709.62% | -1430.22% | -2066.99% | -1373.71% | -714.51% | -1182.98% | -1429.59% | -732.1% | -718.14% | -2009.36% | -3931.81% | -4643.02% | -469690.63% | -11200.53% | - |
| Income Tax | 0 | 0 | 0 | 0 | -661.66K | 0 | 0 | 0 | 50.5K | 0 | 0 | 0 | 636.5K | 0 | 0 | 0 | 448.58K | 89.34K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 3.26% | 0% | 0% | 0% | -0.65% | 0% | 0% | 0% | -6.77% | 0% | 0% | 0% | -25.45% | - |
| Net Income | -84.33M | -12.2M | -13.98M | -25.74M | -19.66M | -25.88M | -19.39M | -10.09M | -7.75M | -6.53M | -4.79M | -6.83M | -9.41M | -7.42M | -4.49M | -1.35M | -2.89M | -1.76M |
| Net Margin % | -11581.34% | -751.39% | -859.13% | -1709.62% | -1383.65% | -2066.99% | -1373.71% | -714.51% | -1182.98% | -1429.59% | -732.1% | -718.14% | -2009.36% | -3931.81% | -4643.02% | -469690.63% | -18378.53% | - |
| Net Income Growth % | -503.68% | 12.75% | 45.67% | -30.93% | 24.06% | -33.49% | -92.25% | -30.21% | -18.7% | -36.23% | 29.9% | 27.35% | -26.73% | -65.42% | -231.7% | 53.23% | -64.09% | - |
| Net Income (Continuing) | -84.01M | -10.86M | -12.02M | -25.74M | -19.66M | -25.88M | -19.39M | -10.09M | -6M | -6.53M | -4.79M | -6.83M | -9.41M | -7.42M | -4.49M | -1.35M | -2.89M | -1.76M |
| Discontinued Operations | -322.86K | -1.8M | -1.97M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -116.48 | -2.24 | -3.48 | -6.98 | -7.20 | -44.25 | -137.20 | -157.40 | -188.69 | -462.28 | -306.79 | -737.17 | -1070.11 | -1786.32 | -52786.81 | -609.33 | -1606.79 | -2562.50 |
| EPS Growth % | -3436.58% | 35.63% | 50.14% | 3.06% | 83.73% | 67.75% | 12.83% | 16.58% | 59.18% | -50.68% | 58.38% | 31.11% | 40.09% | 96.62% | -8563.11% | 62.08% | 37.3% | - |
| EPS (Basic) | - | -2.24 | -3.48 | -6.98 | -7.16 | -44.25 | -137.14 | -157.40 | -188.69 | -462.28 | -306.79 | -737.17 | -1070.11 | -1786.32 | -52786.81 | -609.33 | -1606.79 | -2562.50 |
| Diluted Shares Outstanding | 724K | 5.45M | 4.01M | 3.69M | 2.74M | 597.51K | 143.5K | 64.08K | 31.82K | 14.12K | 15.62K | 9.27K | 8.79K | 4.16K | 90 | 2.22K | 1.8K | 694 |
| Basic Shares Outstanding | 724K | 5.45M | 4.01M | 3.69M | 2.73M | 584.99K | 141.33K | 64.08K | 31.82K | 14.12K | 15.62K | 9.27K | 8.79K | 4.16K | 90 | 2.22K | 1.8K | 694 |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Imminent liquidity exhaustion
According to the most recent quarterly financial data, Predictive Oncology's revenue has plummeted to a negligible $3.6K, representing a 99% year-over-year decline that underscores the company's inability to maintain a consistent commercial footprint across its Helomics, zPREDICTA, and Skyline business segments.
The precipitous drop in top-line performance suggests that the company's project-based service model is failing to secure the recurring biopharma contracts necessary for stability. This collapse in revenue indicates that the firm's proprietary biobank and AI platform have yet to achieve meaningful market penetration or commercial validation.
As reported in financial statements, the company's gross margin has deteriorated into negative territory at -131%, a stark reversal from the 59.1% margin observed in early 2025, reflecting an inability to cover the direct costs associated with its specialized laboratory and hardware operations.
The volatility in gross margins suggests that the cost of revenue is highly sensitive to low volume, as fixed laboratory overheads cannot be absorbed by the current minimal sales. Investors should monitor whether this negative margin is a temporary anomaly or a permanent feature of a business model that lacks the scale to achieve operational efficiency.
Based on reported figures, the company's operating margin has reached an unsustainable -906.5%, highlighting a massive disconnect where SG&A expenses continue to dwarf the company's ability to generate even basic revenue, effectively preventing any path toward operational self-sufficiency or meaningful scale.
The persistent reliance on high SG&A spending despite a collapsing revenue base suggests that the company's current cost structure is misaligned with its commercial reality. This lack of operating leverage implies that the firm is currently unable to scale its AI-driven services without incurring disproportionate overhead costs.
Data from recent filings indicates that with cash reserves dwindling to approximately $734,673, the company faces an existential risk, as the current burn rate significantly exceeds the remaining liquidity, leaving little room for error in executing a turnaround or securing additional capital.
Short-sellers would likely focus on the extreme disparity between the company's high-tech AI narrative and the reality of its rapidly depleting cash position. The lack of material revenue growth suggests that the market may be correctly discounting the firm's ability to survive as a going concern without significant dilution or asset liquidation.
Quick answers to the most common questions about buying POAI stock.
For fiscal year 2024, Predictive Oncology Inc. (POAI) reported total revenue of $1.6M.
Predictive Oncology Inc. (POAI) reported a net loss of $12.2M for the fiscal year ending 2024.
Predictive Oncology Inc. (POAI) reported an operating income of $-10.9M, resulting in an operating profit margin of -673.7%. This margin reflects the operational efficiency of the business before interest and taxes.
Predictive Oncology Inc. (POAI) generated $0.8M in gross profit for the year, representing a gross profit margin of 49.1%. This demonstrates the company's core pricing power and production efficiency.